Business Context and Reporting Period
This February 23, 2023 Form 8-K was filed by Anzu Special Acquisition Corp I, a special purpose acquisition company (SPAC), not by Envoy Medical, Inc. The filing reports an agreement related to extending Anzu’s deadline to complete an initial business combination. The report was signed February 24, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity balances, trust-account balances, or other operating financial metrics.
Material Changes Versus the Prior Comparable Period
- Anzu and its sponsor entered into extension support agreements with several unaffiliated holders in connection with a proposed extension of the business-combination deadline from March 4, 2023 to September 30, 2023, or an earlier date determined by the board.
- The holders agreed to notify the sponsor of intended redemptions and retained shares and to vote an aggregate of 3,311,894 public shares in favor of the extension proposal.
- In exchange, immediately after an initial business combination, the sponsor agreed to transfer 20,000 founder shares for each 100,000 public shares held by a holder after the special meeting, subject to a maximum of 80,000 founder shares per holder.
Guidance, Outlook, Risks, and Unusual Items
The agreements are intended to increase the likelihood that the extension proposal will be approved and may increase the funds remaining in Anzu’s trust account. The filing provides no assurance that the proposal will be approved, that sufficient trust-account funds will remain to satisfy conditions of the letter of intent with the intended business-combination target, or that a business combination will be completed.
Key risks include stockholder redemptions, failure to obtain required approvals, delays or failure to complete the business combination, regulatory issues, changing market and financial conditions, and other risks identified in Anzu’s proxy statement and SEC filings. The transfer of founder shares is a contingent and unusual transaction that would occur only after completion of an initial business combination.
Important Facts for Investors to Verify
- Confirm whether stockholders approved the extension proposal before the March 4, 2023 deadline.
- Verify the number of shares actually redeemed and the resulting balance of the trust account.
- Review the letter of intent and determine whether the intended target was Envoy Medical, Inc. and whether transaction conditions were satisfied.
- Assess the potential dilution from the sponsor’s contingent transfer of founder shares.
- Review Exhibit 10.1 for the complete terms of the extension support agreements.